# Newton Biocapital

> Newton Biocapital is a VC fund in Brussels backing Biotechnology and Medical. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Brussels, Belgium
- Total investments: 22
- Last investment: Dec 2025
- Lead investor: 68%
- Last fund: Feb 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/newton-biocapital-fund/about/
- X (Twitter): https://twitter.com/newtonbiocapita?lang=en
- Website: https://www.newtonbiocapital.com/

Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases.Their approach as lead investor is to support promising start-up projects as well as neglected or undervaluedlate-stage projects, in order to mitigate the risks and to create investor value. The leadership team consi.sts of specialists with long-standing management and investor experience who coach bio-entrepreneurs through the development stages of their projects.

## Contacts

5 contacts available for Newton Biocapital. Shizune tracks 4 team members at Newton Biocapital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/newton-biocapital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.7M–$3.2M |
| Series A | $6.1M–$84M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 55% |
| Medical | 9 | 41% |
| Health Care | 6 | 27% |
| Pharmaceutical | 6 | 27% |
| Medical Device | 5 | 23% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 36% |
| Funding Round | 4 | 18% |
| Seed | 3 | 14% |
| Series B | 2 | 9% |
| Series D | 2 | 9% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Belgium | 8 | 36% |
| Japan | 4 | 18% |
| France | 3 | 14% |
| Switzerland | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Els Hubloux | Partner | 3 | https://shizune.co/investors/profile/els-hubloux |
| Goro Takeda | Managing Partner | 0 | https://shizune.co/investors/profile/goro-takeda |
| Toshiyuki Mori | Partner, Tokyo | 1 | https://shizune.co/investors/profile/toshiyuki-mori |
| Alain Parthoens | Managing Partner and Founder | 7 | https://shizune.co/investors/profile/alain-parthoens |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bioxodes | Founded by an experienced group of seasoned healthcare and biotech executives with extensive experience in research, drug development, and commercialisation, Bioxodes is developing a portfolio of high value products derived from natural sources based on research conducted by Prof. Edmond Godfroid. The research was conducted in collaboration withacademic groups from Université Catholique de Louvain, Facultés Universitaires Notre Dame de la Paix Namur, and Université de Liège as well as with the Université de Neuchâtel, Switzerland.The Company’s lead programme, Ir-CPI, is the first in a novel class of antithrombotics, and is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention. Thanks to a novel mechanism of action, Ir-CPI is potentially the world’s first injectable antithrombotic which can be used in all patient groups without causing high levels of bleeding and potentially without needing to be reversed or washed out at the end of critical procedures. | $6.4M | Series A | Dec 10, 2025 |  |
| Augustine Therapeutics | Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors and GABABR1a activators for the treatment of neurological diseases such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M | Series A | Mar 24, 2025 |  |
| Tensegrity Pharma | Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients. | $3.2M | Seed | Nov 13, 2024 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. |  |  | Nov 11, 2024 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. | $10.6M | Series A | Nov 11, 2024 |  |
| AbolerIS Pharma | AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance. | $29.2M | Series A | Sep 18, 2023 |  |
| Santero Therapeutics | Santero Therapeutics seeks to provide novel medications with fresh modes of action that combat diseases with high resistance. Santero develops antimicrobials with novel modes of action to combat the rise of antibiotic-resistant microorganisms. | $8.6M | Series A | Jun 07, 2023 |  |
| AdipoPharma | AdipoPharma SAS is dedicated to learning more about the role of adipocyte cells in diabetes. AdipoPharma is using the adipocyte's power to treat insulin resistance, type 2 diabetes, and other diseases. |  | Series A | Jan 23, 2023 |  |
| DeuterOncology | DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies. | $6.1M | Series A | Jan 19, 2023 |  |
| NeuVasQ | NeuVasQ is developing drugs to restore blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, as well as neurodegenerative diseases such as Alzheimer's. It is based on discoveries about the molecular mechanisms that keep the blood-brain barrier intact (BBB). The BBB regulates the exchange of informationbetween the vascular and central nervous systems (CNS). Increased BBB permeability, whether due to age or injury, plays a role in many neurological conditions by allowing harmful blood substances to enter the CNS. Many neurodegenerative disorders, such as Alzheimer's, as well as a variety of acute neurological conditions, such as stroke and epilepsy, are associated with BBB dysfunction. | $23.9M | Series A | Jun 24, 2021 |  |

10 of 22 investments shown.

## Co-investors
- [Sambrinvest](https://shizune.co/investors/profile/sambr-invest) — VC Fund, 5 deals together
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 4 deals together
- [Good Growth Capital](https://shizune.co/investors/profile/good-growth-capital) — VC Fund, 3 deals together
- [Investsud](https://shizune.co/investors/profile/investsud) — VC Fund, 2 deals together
- [InvestSud](https://shizune.co/investors/profile/investsud-9c11) — VC Fund, 2 deals together
- [ITOCHU Technology Ventures](https://shizune.co/investors/profile/itochu-technology-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [All VC Funds in Belgium](https://shizune.co/investors/vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [All Investors in Belgium](https://shizune.co/investors/investors-belgium)
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)

## FAQ

### What does Newton Biocapital invest in?

Newton Biocapital invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Funding Round stage. Most of the 22 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Newton Biocapital's check size?

Newton Biocapital typically joins rounds of $2.7M–$3.2M at Seed and $6.1M–$84M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Newton Biocapital participates in.

### How do I contact Newton Biocapital?

Public channels for Newton Biocapital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Newton Biocapital?

The team at Newton Biocapital includes Els Hubloux (Partner), Goro Takeda (Managing Partner) and Toshiyuki Mori (Partner, Tokyo). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co